LY 301497
Alternative Names: 17beta-HydroxywortmanninLatest Information Update: 22 Aug 2001
Price :
$50 *
At a glance
- Originator Eli Lilly and Company
- Class Androstadienes; Antihypercalcaemics; Osteoporosis therapies; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Malignant hypercalcaemia; Postmenopausal osteoporosis
Most Recent Events
- 22 Aug 2001 No-Development-Reported for Malignant hypercalcaemia in USA (Unknown route)
- 22 Aug 2001 No-Development-Reported for Postmenopausal osteoporosis in USA (Unknown route)
- 07 Aug 1996 Preclinical development for Malignant hypercalcaemia in USA (Unknown route)